Beta

Connect biopharma holdings limitedCNTB.US Overview

US StockHealthcare
(No presentation for CNTB)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

CNTB AI Insights

CNTB Overall Performance

CNTB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CNTB Recent Performance

-2.04%

Connect biopharma holdings limited

-1.10%

Avg of Sector

-0.49%

S&P500

CNTB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check CNTB's Trend

CNTB Key Information

CNTB Valuation Metrics

CNTB Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

Price of CNTB

CNTB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CNTB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.57
PE Ratio (TTM)
-
Forward PE
0.77
PS Ratio (TTM)
2225.53
PB Ratio
3.39
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-201931.25%
Revenue Growth (YoY)
-66.67%
Profit Growth (YoY)
-66.67%
3-Year Revenue Growth
-%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.57
PE Ratio (TTM)
-
Forward PE
0.77
PS Ratio (TTM)
2225.53
PB Ratio
3.39
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-201931.25%
Revenue Growth (YoY)
-66.67%
Profit Growth (YoY)
-66.67%
3-Year Revenue Growth
-%
3-Year Profit Growth
-100.00%

  • When is CNTB's latest earnings report released?

    The most recent financial report for Connect biopharma holdings limited (CNTB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CNTB's short-term business performance and financial health. For the latest updates on CNTB's earnings releases, visit this page regularly.

  • How is CNTB's revenue growth?

    In the latest financial report, Connect biopharma holdings limited (CNTB) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CNTB have?

    As of the end of the reporting period, Connect biopharma holdings limited (CNTB) had total debt of 690K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CNTB have?

    At the end of the period, Connect biopharma holdings limited (CNTB) held Total Cash and Cash Equivalents of 38.35M, accounting for 0.68 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CNTB's EPS continuing to grow?

    According to the past four quarterly reports, Connect biopharma holdings limited (CNTB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CNTB?

    Connect biopharma holdings limited (CNTB)'s Free Cash Flow (FCF) for the period is -11.27M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 29.1% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CNTB?

    The latest valuation data shows Connect biopharma holdings limited (CNTB) has a Price-To-Earnings (PE) ratio of -2.67 and a Price/Earnings-To-Growth (PEG) ratio of -0.15. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.